The Department of Health and Human Services (HHS) has formally backed a proposal by the Drug Enforcement Administration (DEA) to place synthetic kratom extracts under federal scheduling. This regulatory shift follows an announcement made by the DEA in July, which outlined plans to temporarily classify a specific psychoactive compound derived from kratom as a controlled substance.

Kratom, a tropical tree native to Southeast Asia, contains compounds that interact with opioid receptors in the brain. While natural kratom remains legal at the federal level, the DEA and HHS are specifically targeting synthetic versions of these extracts. These products are frequently marketed in convenience stores and smoke shops, leading some health officials to label them as "gas station opioids" due to concerns regarding their potency and potential for abuse.

The HHS recommendation serves as a critical step in the federal scheduling process, signaling alignment between public health authorities and law enforcement regarding the risks associated with these synthetic derivatives. Proponents of the move argue that federal scheduling is necessary to curb the availability of unregulated, potentially dangerous substances. Conversely, advocates for kratom access often argue that such measures could restrict consumer access to natural products and that the risks of synthetic extracts are being conflated with the risks of the plant itself. The DEA's temporary scheduling order is intended to address immediate safety concerns while further research and long-term regulatory frameworks are developed.